

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Health Group Limited**  
**中國衛生集團有限公司**

*(Carrying on business in Hong Kong as CHG HS Limited)*

*(Incorporated in Bermuda with limited liability)*

*(Stock Code: 673)*

**FURTHER EXTENSION OF LONG STOP DATE  
OF DISCLOSEABLE TRANSACTION**

Reference is made to the announcements of China Health Group Limited (the “**Company**”) dated 6 February 2023 and 26 April 2023 in relation to the acquisition of 51% equity interest in Golden Alliance Limited involving the issue of shares under general mandate (the “**Announcements**”). Capitalised terms used herein have the same meanings as defined in the Announcements unless the context otherwise requires.

As disclosed in the announcement of the Company dated 26 April 2023, the Long Stop Date has been extended to 31 May 2023 or such later date as the parties may agree. As the Target Group requires additional time to fulfill the conditions precedent to Completion, the parties to the Agreement have agreed in writing to further extend the Long Stop Date to 30 June 2023 or such later date as the parties may agree.

Save for the above extension of the Long Stop Date, all other terms of the Agreement shall remain unchanged and continue in full force and effect. The Company is of the view that the extension of the Long Stop Date will not have any material adverse impact on the business and operations of the Group.

By Order of the Board  
**China Health Group Limited**  
**Zhang Fan**  
*Chairman of the Board and Executive Director*

Hong Kong, 31 May 2023

*As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Zhang Fan (Chairman) and Mr. Chung Ho; three non-executive Directors, namely, Mr. Xing Yong, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.*